← All Scholar Rock Holding CORP filings

Scholar Rock Holding CORP 8-K filings

NASDAQ
SRRK
Scholar Rock Holding CORP
8-K: Scholar Rock Announces Promising Phase 1 Trial Data for SRK-181 in Advanced Solid Tumors
Scholar Rock presented encouraging Phase 1 trial data for SRK-181 in combination with pembrolizumab, showing anti-tumor activity in multiple cancer types, particularly in patients resistant to anti-PD-(L)1 therapies.
NASDAQ
SRRK
Scholar Rock Holding CORP
8-K: Scholar Rock Advances Muscle-Targeted Therapies with New Clinical Trial and Preclinical Data
Scholar Rock initiates a Phase 2 trial for apitegromab in obesity and presents promising preclinical data for SRK-439, highlighting its potential in preserving lean muscle mass.
NASDAQ
SRRK
Scholar Rock Holding CORP
8-K: Scholar Rock Extends Lease Agreement for Corporate Headquarters
Scholar Rock has extended its lease agreement for its Cambridge headquarters by two years, with an option for a further five-year extension.
NASDAQ
SRRK
Scholar Rock Holding CORP
8-K: Scholar Rock Reports Q1 2024 Financial Results and Provides Business Update
Scholar Rock announced its first quarter 2024 financial results, highlighted by progress in its SMA and cardiometabolic programs, and a cash runway extending into the second half of 2025.
NASDAQ
SRRK
Scholar Rock Holding CORP
8-K: Scholar Rock Reports Full Year 2023 Results and Provides Pipeline Update
Scholar Rock announced its full year 2023 financial results and provided updates on its clinical programs, including the Phase 3 SAPPHIRE trial for spinal muscular atrophy and a new Phase 2 trial for obesity.
NASDAQ
SRRK
Scholar Rock Holding CORP
8-K: Scholar Rock Expands Board with Neurology Expert and Promotes Key Research Leader
Scholar Rock appoints Katie Peng to its Board of Directors and promotes Mo Qatanani to Chief Scientific Officer, signaling a focus on commercialization and research advancement.